Fuhong Hanlin's revenue exceeded 2.5 billion yuan in the first half of 2023, and its self-developed products reached over 40 global markets
Fuhong Hanlin recently released its mid-term performance for 2023, achieving a net profit of approximately RMB 240 million and operating revenue of approximately RMB 2.5005 billion during the performance period, an increase of approximately 93.9% compared to the same period last year. This is mainly due to the continuous growth in sales revenue of the company's core products, Hanqu You ® And Hans shape ® Achieved sales revenue of approximately 1.2767 billion yuan and 556.3 billion yuan respectively.
While accelerating global business expansion, Fuhong Hanlin continues to invest more in innovative research and development, with a research and development investment of approximately RMB 673.8 million in the first half of 2023.
As an international innovative biopharmaceutical company, Fuhong Hanlin's products cover fields such as tumors, autoimmune diseases, and ophthalmic diseases. The reporter learned that as of now, Fuhong Hanlin has launched 5 self-developed products, reaching over 40 markets worldwide. More than 10 registration applications have been accepted by drug regulatory authorities in multiple countries and regions such as China, the United States, the European Union, Brazil, Canada, Indonesia, Singapore, and benefiting over 450000 patients.
Zhang Wenjie, Chairman and Executive Director of Fuhong Hanlin, stated, "In the first half of 2023, Fuhong Hanlin achieved remarkable performance thanks to Hanquyou." ® And Hans shape ® The two products have accelerated and increased in volume, and the company's revenue has grown rapidly, achieving a semi annual profit for the first time. While continuously 'self generating blood' and increasing kinetic energy, we have improved our internal skills, honed our system, and built a 'moat', laying a solid foundation for long-term sustainable high-quality development. It is expected to create a more brilliant chapter in global competition
As the company's core anti-tumor product, Hanquyou ® In the first half of 2023, global sales reached approximately 1.2767 billion yuan, a year-on-year increase of 57.1%. Among them, Han Quyou ® The market share in China has further expanded, with consecutive monthly sales exceeding 200 million since March 2023. In the first half of 2023, the sales revenue was approximately RMB 1.2471 billion, an increase of approximately 55.8% compared to the same period last year. In addition, Han Quyou ® Realized sales and licensing revenue of approximately 32.8 million yuan in overseas markets, a year-on-year increase of 120.1%.
As of now, Han Quyou ® It has been approved for marketing in more than 40 countries and regions including China, the United Kingdom, Switzerland, Australia, Singapore, Argentina, Saudi Arabia, and has become the most domestically produced biosimilar drugs approved for marketing in these countries and regions. In the first half of 2023, Han Quyou ® The application for market authorization in the United States has also been accepted by the US Food and Drug Administration and is expected to be approved in the second half of the year, further covering the mainstream biopharmaceutical markets in Europe and America, and benefiting more patients worldwide.
In the first half of 2023, Fuhong Hanlin continued to implement and deepen its differentiated innovation strategy, steadily expanding its clinical layout globally, strengthening the integration and cooperation of innovation centers between China and the United States, actively exploring new targets and mechanisms, and continuously expanding its product disease field and new molecular types.
At present, the company has proactively laid out a diversified and high-quality product pipeline, covering more than 60 molecules, including monoclonal antibodies, dual antibodies, antibody conjugated drugs, recombinant proteins, small molecule conjugated drugs and other drug forms. More than 80% of the products are independently developed.
Fuhong Hanlin stated that in the future, the company will deepen its internationalization strategy, continuously improve its operational and innovation efficiency, strengthen cooperation with international partners, and open up broader space for the company's global development.
Text: Yang Zhenying
